Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Description
CONCLUSIONS: High-dose pemetrexed appears tolerable and shows objective antitumor activity in patients with chordoma. Phase II studies of high-dose pemetrexed are warranted.
